CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
PvDBPII/Matrix-M1biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04201431
NCT04201431Phase 2Completed
CompareCT.gov

A Phase I/IIa Clinical Trial to Assess the Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1 in Healthy Adults Living in the UK

University of Oxford·interventional·Posted Dec 17, 2019·Updated Nov 25, 2024

In Brief

A Phase 2 clinical trial evaluating PvDBPII/Matrix-M1 for Malaria, Vivax. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This is an Open label, first-in-human, Phase I/IIa, blood-stage P. vivax malaria vaccine trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium vivax malaria vaccine candidate PvDBPII in Matrix M1 in healthy adults living in the UK.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria, Vivax
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 17, 2019
Enrollment StartJan 24, 2020
Primary CompletionJul 14, 2022
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 6.5 years ago

Interventions

PvDBPII/Matrix-M1biological

50ug PvDBPII in 50ug Matrix M1